News

Focusing on Rare Diseases, CGeneTech Research Develops New Drug Expected to Bring Gospel to Patients with Multiple Sclerosis

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2019-02-28
  • Views:0

(Summary description)Today is the 12th International Rare Disease Day. Remember the Ice Bucket Challenge that took the world by storm in 2014 and sparked the attention of the community to rare diseases including acromegaly? Teriflunomide, a new class 3.1 drug developed by CGeneTech, has recently officially launched a clinical trial for consistency evaluation against multiple sclerosis similar to acromegaly, which is expected to bring gospel to domestic multiple sclerosis patients!

Focusing on Rare Diseases, CGeneTech Research Develops New Drug Expected to Bring Gospel to Patients with Multiple Sclerosis

(Summary description)Today is the 12th International Rare Disease Day. Remember the Ice Bucket Challenge that took the world by storm in 2014 and sparked the attention of the community to rare diseases including acromegaly? Teriflunomide, a new class 3.1 drug developed by CGeneTech, has recently officially launched a clinical trial for consistency evaluation against multiple sclerosis similar to acromegaly, which is expected to bring gospel to domestic multiple sclerosis patients!

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2019-02-28
  • Views:0

Today is the 12th International Rare Disease Day. Remember the Ice Bucket Challenge that took the world by storm in 2014 and sparked the attention of the community to rare diseases including acromegaly? Teriflunomide, a new class 3.1 drug developed by CGeneTech, has recently officially launched a clinical trial for consistency evaluation against multiple sclerosis similar to acromegaly, which is expected to bring gospel to domestic multiple sclerosis patients!

Multiple sclerosis is the most common type of central nervous demyelinating disease, characterized by speech, vision, motor and sensory impairments and cerebral neuropathies. It was reported in 2013 that scientists at Hopkins found that amyotrophic lateral sclerosis, or what we commonly call acromegaly, may have something in common with multiple sclerosis. Multiple sclerosis researchers may be able to interface with some of the same treatments that slow the progression of amyotrophic lateral sclerosis, thus opening the door to a treatment for acromegaly.

Currently, multiple sclerosis affects more than 350,000 people in the United States, 40-50,000 domestically, and approximately 2.5 million worldwide. Symptoms usually appear in the 20s and 40s, with twice as many women as men suffering from the disease, and most patients are in the relapse phase of the disease. The goal of treating MS is to reduce the duration and worsening of symptoms associated with relapses, prevent the incidence of relapses, and delay the accumulation of the disease.

The development of drugs for the treatment of rare diseases has not been forgotten by society. Many countries around the world, especially some developed countries, have generally established systems to encourage the development of therapeutic drugs for rare diseases.In 2013, the State Drug Administration issued [2013] No. 37, which clearly prioritized the review of innovative and generic drugs for the treatment of rare diseases.


On May 22, 2018, the Health Planning Commission included multiple sclerosis in the rare disease catalog, which accelerated the approval process of related drugs. Therefore, the drug independently developed by Centurion Technology only needs to complete the drug consistency evaluation on healthy human bodies before it can apply for marketing and sales. According to Dr. Qiang Yu, CEO of CGeneTech, the completed clinical pre-experiments have met the standards, and the API and formulation levels are the same as those of the original product, and all experimental content is expected to be completed this year. At present, there is no similar product in China except for the import of Teriflunomide from the original research manufacturer Sanofi. Teriflunomide from CGeneTech will be of the same quality as the foreign original research and at a favorable price to relieve the pain of domestic MS patients.

Shengshi

Shengshi Taike has been awarded the "Double Yellow Egg" of Jiangsu Province's innovation and entrepreneurship talents

Jiangxiang is near Xiaoman, with warm air and moving grasshoppers. Recently, the selection results of Jiangsu Province's "Double Innovation Plan" for 2024 have been officially announced. Shengshi Taike's talent team has won the "Double Yellow Egg" award: the core team led by Dr. Wang Tong, Chief Scientific Officer, has been successfully selected as the "Double Innovation Team" in Jiangsu Province in 2024, and is the only "Innovation Team" in the field of biomedicine in Suzhou; Dr. Zhao Jiahong, Chief Medical Officer, has been successfully selected as a "Double Innovation Talent" in Jiangsu Province in 2024. The "Double Innovation Plan" in Jiangsu Province mainly focuses on introducing and funding scarce talents in the "high-precision and cutting-edge" and "bottleneck" fields, supporting the development of new technologies in key areas, and is an important brand project for talent work in Jiangsu Province. This plan focuses on the key industries prioritized for development in Jiangsu Province, playing an important role in enhancing independent innovation capabilities, promoting industrial structure optimization and upgrading, and driving rapid economic development. Dr. Wang Tong was just awarded the title of "Double Innovation Talent" in Jiangsu Province last year, and this time he led the company's core team to win the honor of "Double Innovation Team" in Jiangsu Province, fully reflecting the continuous innovation ability of the company's talent team. Dr. Wang Tong, as the Chief Scientific Officer of Shengshi Taike, has over 20 years of experience in the full chain drug research and management of top pharmaceutical companies and research institutes in the United States. He is a strategic scientist who can break through key technologies, drive emerging disciplines, and promote the new drug industry. Since joining Shengshi Taike, I have been awarded the title of leading technology talent at all levels, bringing innovative thinking and advanced technological means to the company. I have integrated and formed a complete new drug development and industrialization platform, leading the company's R&D team to accelerate the development of the new drug product pipeline. One of the core product pipelines, the hypoglycemic drug sengliptin, has been launched for sale. Dr. Zhao Jiahong, a core member of the "Double Creation Team", was also awarded the honor of "Double Creation Talent" in Jiangsu Province this time. Dr. Zhao Jiahong, as the Chief Medical Officer of Shengshi Taike, has over 20 years of experience in drug clinical trials and team management, and is an external expert of CDE; Has rich practical experience in medical affairs and early drug development, clinical development strategies, and international multicenter clinical trials, and has led and participated in over 600 clinical projects; I also have some experience in post market re evaluation of drugs. Since joining Shengshi Taike, I have been fully responsible for the company's new drug clinical development strategy and pathway, as well as post market expansion research and other important tasks. Among the core members of the "Double Creation Team", Dr. Lu Qin graduated from Fudan University with a major in Medical Systems Biology and holds the associate senior professional title. She has achieved fruitful research results in the field of biology, published multiple high-quality papers, obtained nearly 10 authorized invention patents, led the company's biology team to complete multiple project research tasks, and won multiple honors such as leading the park. Dr. Ouyang Zhenwu graduated from the Organic Chemistry Department of the Chinese Academy of Sciences. He has demonstrated outstanding academic and professional achievements in the field of pharmaceutical chemistry. He has published six high-quality papers in internationally renowned chemical journals, demonstrating his profound skills in chemical synthesis and drug design. Since joining the company, Dr. Ouyang has repeatedly used "innovative synthesis methods" to simplify the synthesis route, which not only significantly improves the efficiency of new drug screening, but also saves costs for the company in new drug development. Shengshi Taike, composed of these innovative talent teams, is a biotechnology company in the commercial stage. The core team has decades of experience in the entire lifecycle of international drugs and is committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives.
2025-05-22
Media

Media Attention | Yu Qiang, an "unsmart" entrepreneur, and his new diabetes drug Sengliptin

Qiang Yu, the founder and CEO of CGeneTech, a doctor of chemistry from Peking University, founded a biotechnology company in the United States at the beginning of this century, and later returned to China to found CGeneTech and developed a new type 2 diabetes drug, a new generation of DPP-4 inhibitor senpaglitin, which has now been approved for marketing.
2025-04-16

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO